Solutions Series 2026
May 14-15, 2025
Join us on May 14 and 15 in Washington, D.C., for our 2nd annual SPRING Summit, where we’ll work together to plan and activate core components of our Roadmap to Recovery. At our 2025 SPRING Summit, we’ll focus on the emotional and social isolation that causes traumatic stress, additional medical issues and lost productivity for people with schizophrenia and their care partners.
SPRING Initiative
SPRING is a collaboration of people with lived experience, treatment providers, researchers, community leaders and policymakers – all of whom share a mission to ensure people living with schizophrenia have access to proper treatment and are given the chance to recover and thrive.
SPRING Summit 2025
May 14-15, 2025
Join us on May 14 and 15 in Washington, D.C., for our 2nd annual SPRING Summit, where we’ll work together to plan and activate core components of our Roadmap to Recovery. At our 2025 SPRING Summit, we’ll focus on the emotional and social isolation that causes traumatic stress, additional medical issues and lost productivity for people with schizophrenia and their care partners.
SPRING Summit 2024
May 15, 2024
S&PAA’s inaugural Schizophrenia Policy and Research Institute NextGen (SPRING) Summit in Washington, D.C., was a unique and groundbreaking collaboration to create a roadmap for transforming the fragmented system of care for people with schizophrenia into a path toward recovery. Participants represented the diverse range of stakeholders in the schizophrenia journey: those diagnosed with the disease, care partners, judges, law enforcement, researchers, community leaders and policymakers.
Capitol Hill Briefing Speaker Bios
Go Back People With Schizophrenia Face Severe Treatment Barriers Regulatory, policy solutions urgently needed to address inequity ANALISA CHASE Analisa Chase of Tacoma, WA, is a behavior interventionist who works to improve the quality of life for people on the autism spectrum. In 2016, at age 24, she was diagnosed with schizoaffective disorder – a […]
PFDD Livestream Page
Nov 2, 2022
the schizophrenia community will finally have the spotlight, as those living with the condition and their family members share their treatment needs and concerns with drug developers and FDA staff. The Externally-Led Patient Focused Drug Development (PFDD) meeting offers the chance to make what matters to those living with the neurobiological brain disease a higher priority in drug development and the FDA review process.
Events
All past and upcoming events
Stay Informed
Stay Informed